Please login to the form below

Not currently logged in
Email:
Password:

House of Lords says NICE must disclose Alzheimer's model

The National Institute for Health and Clinical Excellence (NICE) has been told by the House of Lords that it cannot appeal against an earlier high court ruling

The National Institute for Health and Clinical Excellence (NICE) has been told by the House of Lords that it cannot appeal against an earlier high court ruling that it must disclose the model it used in determining which patients can be treated with Alzheimer's drugs on the NHS.

NICE ruled that Eisai's Aricept (co-marketed by Pfizer), Novartis's Exelon, and Reminyl, which is co-developed by Shire and Janssen, were too expensive to provide to patients who are not in the moderate stages of Alzheimer's. This means thousands in the early and later stages of the disease are denied treatment.

"Today is a small victory in the battle to see justice for thousands of people with Alzheimer's disease and their families. Having access to NICE's model will allow us to scrutinise NICE's calculation and to try and make sense of this unfathomable decision," said Neil Hunt, chief executive of Alzheimer's Society.

"We strongly believe that NICE's decision to deny people in the early stages of Alzheimer's disease access to drugs is fundamentally flawed. For the price of a cup of coffee, drug treatments can give people hope, dignity and time when it is the most precious."

30th October 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics